Skip to content

Lung adenocarcinoma — Histology and classification

TL;DR — The 2011 IASLC/ATS/ERS classification replaced “bronchioloalveolar carcinoma” and “mixed subtype” with reproducible categories tied to invasion: adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and invasive adenocarcinoma quantified by predominant growth pattern (Travis 2011, PMID 21252716). The 2021 WHO framework retains morphology first, adds a dedicated small-sample approach, emphasizes molecular testing, and incorporates the IASLC grade based on predominant pattern plus the proportion of high-grade architecture (Nicholson 2022, PMID 34808341). Completely resected AIS/MIA have near-zero disease-specific recurrence in long follow-up, whereas solid, micropapillary, complex-glandular patterns and spread through air spaces (STAS) identify greater recurrence risk (Yotsukura 2021, PMID 33915249; Hegedűs 2024, PMID 38485464; Chen 2019, PMID 30914285). Histology remains clinically useful in the genomic era, but sampling error, interobserver variation, and within-tumor heterogeneity limit any attempt to turn one pattern into a stand-alone treatment biomarker.

Why classification changed

The pre-2011 label “bronchioloalveolar carcinoma” covered lesions ranging from non-invasive ground-glass nodules to diffuse mucinous invasive cancer. The IASLC/ATS/ERS system abolished that term, created separate rules for resections versus small biopsy/cytology, required comprehensive subtyping in 5% increments, and linked diagnosis to tissue preservation for molecular testing (Travis 2011, PMID 21252716; Tang 2014, PMID 25349710).

Retired or ambiguous term Current concept Why the change matters
Bronchioloalveolar carcinoma AIS, MIA, lepidic-predominant invasive adenocarcinoma, or invasive mucinous adenocarcinoma Separates indolent non-invasive lesions from lethal invasive disease (Travis 2011, PMID 21252716)
Mixed-subtype adenocarcinoma Predominant pattern plus percentages of all patterns Makes heterogeneity visible and supports grading (Lee 2012, PMID 23086014)
NSCLC-NOS whenever morphology is limited Morphology plus minimal immunohistochemistry, preserving tissue for genomics Histology and genotype both direct treatment (Nicholson 2022, PMID 34808341)
“BAC pattern” on biopsy Adenocarcinoma with lepidic pattern; invasion cannot be excluded AIS/MIA require complete evaluation of a resection specimen (Travis 2011, PMID 21252716)

The 2015 WHO adopted the IASLC/ATS/ERS architecture, and the 2021 WHO preserved its morphology-first logic while increasing attention to molecularly defined entities and small diagnostic samples (Kuhn 2018, PMID 30259909; Nicholson 2022, PMID 34808341). Radiology and pathology are correlated but not interchangeable: ground-glass opacity often maps to lepidic growth, yet imaging cannot prove absence of microscopic invasion (Lee 2012, PMID 23086014).

AIS, MIA, and invasive adenocarcinoma

Category Core pathologic requirement Staging implication Outcome signal
Atypical adenomatous hyperplasia Small localized proliferation of mildly atypical type II pneumocytes/club cells Preinvasive lesion May share early drivers with adenocarcinoma; progression is not inevitable (Zhu 2023, PMID 36325966)
AIS ≤3 cm, pure lepidic growth, no stromal/vascular/pleural invasion pTis (adenocarcinoma) Essentially 100% disease-specific survival after complete resection in pooled/long-term series (Behera 2016, PMID 27137345; Yotsukura 2021, PMID 33915249)
MIA ≤3 cm, lepidic predominant, invasive focus ≤5 mm, no disqualifying invasion pT1mi Near-100% disease-specific survival after complete resection (Behera 2016, PMID 27137345)
Lepidic-predominant invasive Invasion >5 mm or another invasive criterion T category uses invasive size in current staging Better prognosis than acinar/papillary/solid/micropapillary groups, stage held constant (Okada 2013, PMID 23566969)

A pooled analysis supported staging AIS as pTis and MIA as pT1mi, while also showing that inconsistent historical pathology review can contaminate outcome estimates (Behera 2016, PMID 27137345). In a series of 524 completely resected AIS/MIA cases followed beyond five years, no lung-cancer recurrence occurred; second primary lung cancers remained possible and should not be mislabeled recurrence (Yotsukura 2021, PMID 33915249).

A retrospective surgical series of 1,644 AIS/MIA cases reported excellent survival after both wedge and anatomic resections, with fewer complications after wedge resection; selection by nodule location and pathology prevents causal equivalence claims (Zhang 2022, PMID 33485660). A prospective confirmatory study of sublobar resection based on frozen-section AIS/MIA diagnosis is ongoing because frozen section can misclassify invasion and high-grade foci (Zheng 2024, PMID 39444881).

Invasive nonmucinous patterns

Invasive nonmucinous adenocarcinoma is recorded semiquantitatively by lepidic, acinar, papillary, micropapillary, and solid patterns. Predominant pattern carries prognostic information independent of TNM stage in multiple resection cohorts, with lepidic at the favourable end and solid/micropapillary at the adverse end (Okada 2013, PMID 23566969; Kuhn 2018, PMID 30259909).

Pattern Morphologic anchor Typical risk interpretation Important caveat
Lepidic Tumor cells grow along preserved alveolar septa Low grade when predominant and invasive criteria limited Biopsy cannot exclude unsampled invasion
Acinar Round/oval malignant glands Intermediate Common and heterogeneous
Papillary Fibrovascular cores lined by tumor Intermediate Must distinguish from micropapillary tufts
Micropapillary Small tufts lacking fibrovascular cores, often in air spaces High grade; lymphatic and recurrence associations Small components may matter even when not predominant
Solid Sheets lacking gland formation, with mucin evidence where needed High grade Poorly differentiated mimics require immunophenotyping
Complex glandular Cribriform/fused glands and related complex architecture High grade in IASLC system Recognition reproducibility requires training (Rokutan-Kurata 2021, PMID 33905897)

The classification is not merely descriptive. Histologic subtype remained independently prognostic in post-2011 analyses (Okada 2013, PMID 23566969), and a 631-patient validation found that the IASLC grade stratified outcomes while filigree micropapillary and discohesive patterns added adverse information (Zhang 2023, PMID 36481678). A large Japanese validation also supported the grade’s recurrence discrimination (Rokutan-Kurata 2021, PMID 33905897).

IASLC/WHO grade

The IASLC grade combines the predominant pattern with the proportion of high-grade patterns rather than using predominant pattern alone. Grade 1 is lepidic-predominant with <20% high-grade components; grade 2 includes acinar or papillary predominance with <20% high-grade components; grade 3 includes any tumor with ≥20% solid, micropapillary, or complex-glandular pattern (Nicholson 2022, PMID 34808341; Rokutan-Kurata 2021, PMID 33905897).

Grade Operational definition Expected ordering
1 Lepidic predominant; <20% high-grade patterns Lowest recurrence risk
2 Acinar/papillary predominant; <20% high-grade patterns Intermediate
3 ≥20% solid, micropapillary, or complex glandular Highest recurrence risk

A 2024 systematic review/meta-analysis found worse overall and recurrence-free survival with increasing IASLC grade, supporting external prognostic validity (Hegedűs 2024, PMID 38485464). Retrospective validations in 631 resected stage I–III cases and 2,467 resected cases further support discrimination, but both are vulnerable to treatment-era and centre effects (Zhang 2023, PMID 36481678; Hou 2023, PMID 36748132).

Alternative grading proposals continue because reproducibility and calibration are imperfect. A stage-I cohort proposed a simpler competing system and explicitly cited poor clinical reproducibility of existing schemes (Wang 2024, PMID 38273667). A CT-based model predicted grade 3 in retrospective training and validation cohorts, but prediction cannot replace histologic review until prospective calibration and clinical utility are shown (Wang 2023, PMID 37805451).

Spread through air spaces

STAS describes detached micropapillary clusters, solid nests, or single tumor cells beyond the main tumor edge within alveolar spaces. It is treated as an invasive pattern, not a separate histologic subtype (Chen 2019, PMID 30914285).

STAS question Evidence What remains uncertain
Prognosis Systematic review/meta-analysis associates STAS with worse recurrence and survival in NSCLC, particularly adenocarcinoma (Chen 2019, PMID 30914285) Retrospective pathology and surgical-selection bias
Sublobar resection Recurrence signal appears stronger after limited resection (Yin 2020, PMID 32912289) Whether STAS is causal, a marker of aggressive biology, or partly artifact
Preoperative CT Solid morphology, larger size, and high solid proportion associate with STAS (Gu 2023, PMID 36583661) Imaging is insufficiently accurate for exclusion
Radiomics Network meta-analysis reports promising models (Liu 2024, PMID 38348387) External prospective validation and scanner robustness lacking

STAS assessment is sensitive to specimen handling; displaced tumor fragments may mimic genuine aerogenous spread. Its strongest current use is risk description after resection, not a validated preoperative rule that alone determines lobectomy versus sublobar resection.

Invasive mucinous adenocarcinoma

Invasive mucinous adenocarcinoma (IMA) consists of mucin-rich goblet or columnar cells and often presents with pneumonic, multifocal, or multilobar disease. Most are KRAS-driven, while NRG1 and ERBB2 fusions define subsets, especially among KRAS-wild-type tumors (Chang 2024, PMID 37867404).

IMA dimension Characteristic
Imaging/presentation Pneumonic consolidation, multifocal or multilobar involvement more frequent than in nonmucinous adenocarcinoma (Chang 2024, PMID 37867404)
Spread Genomic similarity among multiple lesions often supports intrapulmonary metastasis rather than synchronous primaries (Chang 2024, PMID 37867404)
Genomics KRAS common; NRG1/ERBB2 and other fusions enrich in KRAS-wild-type disease (Masago 2025, PMID 40634197)
Prognosis after resection Stage and clinicopathologic factors dominate; published series are heterogeneous (Shen 2024, PMID 39455981)

IMA should not be folded into lepidic nonmucinous disease simply because both may grow along alveolar surfaces. Its biology, imaging, spread pattern, and target distribution differ (Chang 2024, PMID 37867404).

Small biopsies, cytology, and tissue stewardship

The 2021 WHO principle is morphology first, supported by a minimal immunohistochemical panel and then molecular methods (Nicholson 2022, PMID 34808341). TTF-1 and Napsin A support adenocarcinoma differentiation; no marker is perfectly sensitive or specific, and mucinous tumors may lack conventional pneumocyte markers. Overuse of stains consumes tissue needed for broad genomic testing.

The safe small-sample label is the most specific diagnosis the material supports. AIS and MIA must not be diagnosed on biopsy because the defining absence or limited extent of invasion requires examination of the entire lesion (Travis 2011, PMID 21252716). Conversely, “NSCLC-NOS” should not persist when morphology and a limited panel can assign lineage, because treatment and molecular-testing pathways diverge (Tang 2014, PMID 25349710).

Histology in the genomic era

Morphology and genomics are complementary. TRACERx analysis of 1,644 regions from 421 NSCLCs showed pervasive subclonal selection and evolutionary dependencies, demonstrating why one biopsy may under-sample both morphology and genotype (Frankell 2023, PMID 37046096). A retrospective pN0M0 cohort found shorter recurrence-free interval in EGFR-mutant than wild-type invasive adenocarcinoma (5-year 85.7% vs 93.3%), but genotype, pattern, and treatment are correlated and the finding is not a stand-alone adjuvant rule (Ito 2018, PMID 30298562).

Open questions

Reproducibility requirement

A grading or STAS rule should show interobserver agreement, sampling adequacy, independent prognostic value beyond stage and genotype, and a prospective treatment interaction before it changes therapy. Prognosis alone is not enough.

  • Does IASLC grade add enough calibrated risk beyond stage, genotype, ctDNA, and radiology to change adjuvant treatment decisions (Hegedűs 2024, PMID 38485464)?
  • Can STAS be distinguished reproducibly from processing artifact, and should it alter the extent of resection prospectively (Chen 2019, PMID 30914285; Zheng 2024, PMID 39444881)?
  • What minimum high-grade component carries clinically meaningful risk: the current 20% grade threshold or smaller micropapillary/solid fractions (Zhang 2023, PMID 36481678)?
  • Can frozen section reliably separate AIS/MIA from invasive disease during sublobar surgery across centres (Zheng 2024, PMID 39444881)?
  • Which KRAS-wild-type IMA fusions are actionable, and can molecular classification improve on morphology alone (Chang 2024, PMID 37867404; Masago 2025, PMID 40634197)?

References

  1. Travis WD, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011. PMID 21252716
  2. Tang Y, et al. The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management. J Thorac Dis. 2014. PMID 25349710
  3. Lee HJ, et al. IASLC/ATS/ERS International Multidisciplinary Classification of Lung Adenocarcinoma: novel concepts and radiologic implications. J Thorac Imaging. 2012. PMID 23086014
  4. Okada M, et al. Subtyping lung adenocarcinoma according to the novel 2011 IASLC/ATS/ERS classification: correlation with patient prognosis. Thorac Surg Clin. 2013. PMID 23566969
  5. Behera M, et al. Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. Clin Lung Cancer. 2016. PMID 27137345
  6. Nakamura H, et al. Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons. Surg Today. 2015. PMID 25417186
  7. Nicholson AG, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022. PMID 34808341
  8. Sasaki T, et al. 2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation. Radiographics. 2024. PMID 38358935
  9. Frankell AM, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023. PMID 37046096
  10. Hou LK, et al. [Application of the WHO Classification of Thoracic Tumors (2021) grading system in invasive pulmonary adenocarcinoma and its correlation with the targeted genes' variations]. Zhonghua Bing Li Xue Za Zhi. 2023. PMID 36748132
  11. Yotsukura M, et al. Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung. J Thorac Oncol. 2021. PMID 33915249
  12. Zhang Y, et al. Surgery for pre- and minimally invasive lung adenocarcinoma. J Thorac Cardiovasc Surg. 2022. PMID 33485660
  13. Ito M, et al. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma. Thorac Cancer. 2018. PMID 30298562
  14. Zhu J, et al. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma. Cancer Med. 2023. PMID 36325966
  15. Zheng S, et al. Sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma diagnosed by intraoperative frozen section (ECTOP-1019): a study protocol of prospective, single-arm, multicenter, phase III study. J Thorac Dis. 2024. PMID 39444881
  16. Chen D, et al. Tumor Spread Through Air Spaces in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Ann Thorac Surg. 2019. PMID 30914285
  17. Yin Q, et al. Meta-analysis of association between CT-based features and tumor spread through air spaces in lung adenocarcinoma. J Cardiothorac Surg. 2020. PMID 32912289
  18. Gu Y, et al. Computed Tomography Features and Tumor Spread Through Air Spaces in Lung Adenocarcinoma: A Meta-analysis. J Thorac Imaging. 2023. PMID 36583661
  19. Liu C, et al. Predictive value of multiple imaging predictive models for spread through air spaces of lung adenocarcinoma: A systematic review and network meta‑analysis. Oncol Lett. 2024. PMID 38348387
  20. Hegedűs F, et al. Prognostic impact of the IASLC grading system of lung adenocarcinoma: a systematic review and meta-analysis. Histopathology. 2024. PMID 38485464
  21. Wang S, et al. Proposed novel grading system for stage I invasive lung adenocarcinoma and a comparison with the 2020 IASLC grading system. Thorac Cancer. 2024. PMID 38273667
  22. Zhang Y, et al. Validation of the novel International Association for the Study of Lung Cancer grading system and prognostic value of filigree micropapillary and discohesive growth pattern in invasive pulmonary adenocarcinoma. Lung Cancer. 2023. PMID 36481678
  23. Rokutan-Kurata M, et al. Validation Study of the International Association for the Study of Lung Cancer Histologic Grading System of Invasive Lung Adenocarcinoma. J Thorac Oncol. 2021. PMID 33905897
  24. Chang WC, et al. Pulmonary invasive mucinous adenocarcinoma. Histopathology. 2024. PMID 37867404
  25. Kuhn E, et al. Adenocarcinoma classification: patterns and prognosis. Pathologica. 2018. PMID 30259909
  26. Shen F, et al. Prognostic factors for resected invasive mucinous lung adenocarcinoma: a systematic review and meta-analysis. BMC Cancer. 2024. PMID 39455981
  27. Masago K, et al. Genomic Landscape of Resected Invasive Mucinous Adenocarcinoma of the Lung. Clin Lung Cancer. 2025. PMID 40634197
  28. Wang K, et al. A pretreatment prediction model of grade 3 tumors classed by the IASLC grading system in lung adenocarcinoma. BMC Pulm Med. 2023. PMID 37805451